secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001193125-24-199382
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Q2 net loss $32.9M; VOWST sales $14.4M (+43% QoQ); announces $175M asset sale to Nestlé
--------------------------------------------------------------------------------

- Net loss $32.9M vs net income $46.6M in Q2 2023 (prior year included $125M VOWST milestone from Nestlé).
- VOWST Q2 net sales $14.4M, up 43% sequentially; Seres share of profit/loss was a $6.6M net loss.
- VOWST asset sale to SPN (Nestlé) provides $175M cash less ~$20M settlement; proceeds to retire Oaktree debt.
- SER-155 Phase 1b Cohort 2 placebo-controlled readout on track for September; SER-147 IND readiness H2 2025.
- Cash $71.2M at June 30; with deal proceeds expects runway into Q4 2025; without deal into Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524199382/0001193125-24-199382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524199382/d881755d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-199382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer